Dambkowski Carl 4
4 · Apogee Therapeutics, Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Apogee Therapeutics (APGE) CMO Carl Dambkowski Exercises Options, Sells Shares
What Happened
- Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), reported exercising options to acquire 4,125 shares at $22.86 per share (cash paid ≈ $94,298) on March 4, 2026. On the same day he sold a total of 5,500 shares in open‑market transactions for aggregate proceeds of approximately $390,825.
- The filing also shows a related derivative disposition of 4,125 shares at $0.00 (reported as a derivative conversion/settlement in connection with the exercise). The transactions were executed under a Rule 10b5‑1 trading plan.
Key Details
- Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (no late‑filing flag shown).
- Exercise (acquired): 4,125 shares @ $22.86 = $94,298.
- Derivative disposition: 4,125 shares @ $0.00 (reported as a derivative conversion/settlement).
- Open‑market sales (total disposed = 5,500 shares, proceeds ≈ $390,825):
- 3,225 shares, weighted avg $70.33 (prices ranged $70.30–$70.82).
- 2,075 shares, weighted avg $71.98 (prices ranged $71.51–$72.45).
- 200 shares, weighted avg $73.26 (prices ranged $73.20–$73.31).
- Shares owned after the transactions: not specified in the materials provided here (check the full Form 4 for post‑transaction holdings).
- Notable footnotes:
- F1: Sales executed pursuant to a Rule 10b5‑1 trading plan adopted Sept 22, 2025 (pre‑planned trades).
- F2–F4: Reported sale prices are weighted averages across multiple transactions; exact per‑trade breakdowns available on request per the footnotes.
- F5: The option underlying these exercises is part of a larger grant (right to purchase 175,345 shares vesting monthly through Dec 18, 2027).
Context
- This was an option exercise combined with immediate open‑market sales. Because the sales were executed under a 10b5‑1 plan, they are generally considered pre‑arranged and routine rather than ad‑hoc insider selling.
- For retail investors: purchases (or unambiguous net buys) are often more indicative of bullish insider sentiment than planned sales. Here, the net economic effect is that shares were acquired via option exercise while a larger number of shares were sold under a pre‑arranged plan.
Insider Transaction Report
Form 4
Dambkowski Carl
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2026-03-04$22.86/sh+4,125$94,298→ 215,273 total - Sale
Common Stock
[F1][F2]2026-03-04$70.33/sh−3,225$226,814→ 212,048 total - Sale
Common Stock
[F1][F3]2026-03-04$71.98/sh−2,075$149,359→ 209,973 total - Sale
Common Stock
[F1][F4]2026-03-04$73.26/sh−200$14,652→ 209,773 total - Exercise/Conversion
Stock Option (Right to Buy)
[F5]2026-03-04−4,125→ 131,290 totalExercise: $22.86Exp: 2033-12-18→ Common Stock (4,125 underlying)
Footnotes (5)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $70.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.51 to $72.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.20 to $73.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.
Signature
/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski|2026-03-06